Skip to main content

Showing 7 matches for the following: Inventor: "Koeberl, Dwight" ×

Gene therapy for long-term treatment of Pompe disease

Gene therapy for long-term treatment of Pompe disease

Unmet Need Pompe disease is a rare heritable disorder impacting heart and skeletal muscle function with an estimated incidence rate of 1 in 40,000 births in the US. Of these affected births, a third take…

Read More

Gene therapy for long-term treatment of GSDIa

Gene therapy for long-term treatment of GSDIa

Unmet Need Glycogen storage disease type Ia (GSDIa), or von Gierke disease, is a rare heritable metabolic disorder that impacts the liver and kidneys due to an inability to break down glycogen. An estimated 1…

Read More

Gene therapy for ATP1A3-Related Neurologic Disorders

Gene therapy for ATP1A3-Related Neurologic Disorders

Unmet Need Children with Alternating Hemiplegia of Childhood can have episodes of temporary paralysis, dystonia, and severe behavioral problems. The prevalence of AHC is estimated to be 1 in one million to 1 out of…

Read More

Clenbuterol Therapy for Amyotrophic Lateral Sclerosis

Clenbuterol Therapy for Amyotrophic Lateral Sclerosis

Unmet Need Amyotrophic lateral sclerosis (ALS) is a debilitating disease with progressive loss of muscle function and inevitable death usually in 3-5 years. There are currently two available therapies on the market which prolong life…

Read More

Muscle mass influences upon response to therapy

Muscle mass influences upon response to therapy

Duke University is seeking a company interested in commercializing a drug treatment method for enhancing lysosomal storage disease therapy by modulating cell surface receptor expression. Lysosmal storage diseases (LSDs), including Pompe disease, Gaucher disease, Farby…

Read More

Method for treating glycogen storage disease

Method for treating glycogen storage disease

The present disclosure is directed to methods of treating a cytoplasmic glycogen storage disorder, including glycogen storage disease I, glycogen storage disease III, glycogen storage disease IV, and/or conditions associated with a PRKAG2 mutation, by…

Read More

Methods of treatment in diseases treated with therapeutic proteins

Methods of treatment in diseases treated with therapeutic proteins

The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us